#National Comprehensive Cancer Network

The ELEVATE program enables access to high-quality smoking cessation care while minimizing costs and burden, finds a new study.

Rates of breast cancer survivors receiving annual mammograms dropped 1.5% per year from 2009 to 2016—and that’s before COVID-19 shutdowns.

A Canadian study finds an immediate cancer diagnosis decrease of 34% in March 2020, followed by a slow and incomplete recovery.

Groups sign letter detailing urgent need to regain lost ground on prevention and early detection and to accelerate cancer research.

The largest peer-reviewed study of the Pfizer-BioNTech COVID vaccine in cancer patients finds no more, and no different, side effects.

The National Comprehensive Cancer Network’s free resource helps cervical cancer patients know what to expect and participate in decisions.

National Comprehensive Cancer Network’s new patient guide covers effective tools for preventing and early detection of colorectal cancer.

People with blood cancers and those on chemotherapy may not respond adequately to their first two vaccine doses.

Basal cell skin cancer is widespread, preventable, and easily-cured cancer but a rare subset requires more aggressive treatment.

New patient/caregiver resource from the National Comprehensive Cancer Network focuses on small cell lung cancer, an aggressive cancer.

The National Comprehensive Cancer Network publishes a new guide that includes updated patient guidelines for colon and rectal cancers.

Study finds 4% of patients with metastatic renal cell carcinoma developed asymptomatic brain metastases, correlating to poorer outcomes.

A new resource for survivors helps guide life after cancer diagnosis and treatment.

People living with cancer are at higher risk for severe illness and death due to COVID-19.

The coronavirus vaccines are safe and should be effective even for people with advanced cancer.

The National Comprehensive Cancer Network and the American Cancer Society are leading efforts to resume cancer screenings and treatment.